CJC-1295 Muscle Growth Results: Comparison Across Protocols
CJC-1295 (DAC) solo, 1mg twice weekly 1.5-2.5kg Convenient dosing (2x/week), sustained GH elevation, minimal injection frequency Slower onset than non-DAC protocols, less pronounced GH pulse amplitude Best for users prioritising convenience and steady baseline
This comparison does not assign a generated winner or score.
- CJC-1295 (DAC) solo, 1mg twice weekly
- 1.5-2.5kg
- Convenient dosing (2x/week), sustained GH elevation, minimal injection frequency
- Slower onset than non-DAC protocols, less pronounced GH pulse amplitude
- Best for users prioritising convenience and steady baseline GH elevation. Ideal for long-term protocols where compliance matters more than peak response
- CJC-1295 (non-DAC) + Ipamorelin, dosed 3x daily
- 2.0-3.5kg
- Stronger GH pulses, synergistic ghrelin/GHRH pathways, faster measurable results
- Requires 3 daily injections, higher total peptide cost, more complex reconstitution schedule
- Highest anabolic potential for experienced users willing to manage multiple daily doses. The synergy between pathways produces the most robust IGF-1 elevation
- CJC-1295 (DAC) + MK-677 (oral), once daily
- 2.5-3.0kg
- Combines pulsatile (CJC) and tonic (MK-677) GH release, simpler than multi-dose protocols, oral component reduces injection burden
- MK-677 increases appetite significantly (ghrelin agonism), potential insulin resistance with prolonged use, water retention common
- Strong option for users in caloric surplus who can manage increased hunger. The dual-pathway approach elevates IGF-1 more consistently than either compound alone
- CJC-1295 (DAC) solo, 2mg once weekly
- 1.0-2.0kg
- Minimal injection frequency, lowest administration burden
- Single large bolus doesn't sustain GH elevation as effectively as split dosing, higher incidence of transient side effects (flushing, headache)
- Least optimal dosing strategy. Splitting the same weekly dose into 2-3 injections produces superior IGF-1 response with fewer acute side effects